Immuron Limited (ASX:IMC) has released the CEO Address delivered by Chief Executive Officer Steve Lydeamore at the company's 2026 Annual General Meeting, covering the company's biopharmaceutical pipeline including Travelan®, IMM-529 and ProIBS®.

Key Points

  • CEO Steve Lydeamore delivered the address at Immuron's 2026 Annual General Meeting on 18 November 2026
  • Immuron is developing IMM-529 as an adjunctive therapy for the prevention and/or treatment of recurrent Clostridioides difficile infection
  • Pre-clinical results for IMM-529 showed prevention of primary disease at 80% (P=0.0052), protection of disease recurrence at 67% (P<0.01) and treatment of primary disease at 78.6% (P<0.0001)
  • Immuron holds an exclusive distribution agreement with Calmino Group AB for ProIBS® across Australia and New Zealand

Travelan® Product and Regulatory Status

According to the filing, Travelan® (IMM-124E) is an orally administered passive immunotherapy indicated to prophylactically reduce the likelihood of contracting travelers' diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709), indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® holds a licensed natural health product designation (NPN 80046016). In the United States, Travelan® is sold as a dietary supplement for digestive tract protection. The product is manufactured from hyperimmune bovine colostrum derived from cattle immunised with a vaccine containing outer antigens of 13 ETEC strains.

IMM-529 Development for Clostridioides Difficile Infection

The filing states that Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection. IMM-529 targets three essential C. diff virulence components: Toxin B (TcB), spores, and surface layer proteins of vegetative cells. Immuron disclosed that IMM-529 is being developed in collaboration with Dr. Dena Lyras and her team at Monash University, Australia. The filing states that, to Immuron's knowledge, IMM-529 is the only investigational drug that has shown therapeutic potential in all three phases of the disease.

ProIBS® Distribution Agreement for Australia and New Zealand

The filing discloses that Immuron holds an exclusive distribution agreement with Calmino Group AB for ProIBS® in the territories of Australia and New Zealand. ProIBS® is described as a certified medical device for the treatment of IBS symptoms including abdominal pain, bloating, and unsettled bowel movements. The product contains AVH200®, derived from the plant Aloe barbadensis Mill. The filing references a usability study conducted among 1,003 users, in which ProIBS® was reported as helpful for 94% of participants, with 91% experiencing an improvement in daily life and 98% stating they would recommend the product to others.